Treatment Patterns and Clinical Outcomes in High-Risk Newly Diagnosed Multiple Myeloma Patients Carrying the 17p Deletion.

This retrospective study reports outcomes among multiple myeloma patients harboring the high-risk del17p mutation. Among the 60 patients enrolled, the overall response rate after induction was 85%. Median overall survival was 43 months. Autologous stem cell transplant was associated with improved overall survival (median, 59.7 vs 28.7 months).

Despite currently available treatment modalities, multiple melanoma patients with the 17p deletion have an inferior prognosis.

https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25098